Literature DB >> 21095075

Cell-specific radiosensitization by gold nanoparticles at megavoltage radiation energies.

Suneil Jain1, Jonathan A Coulter, Alan R Hounsell, Karl T Butterworth, Stephen J McMahon, Wendy B Hyland, Mark F Muir, Glenn R Dickson, Kevin M Prise, Fred J Currell, Joe M O'Sullivan, David G Hirst.   

Abstract

PURPOSE: Gold nanoparticles (GNPs) have been shown to cause sensitization with kilovoltage (kV) radiation. Differences in the absorption coefficient between gold and soft tissue, as a function of photon energy, predict that maximum enhancement should occur in the kilovoltage (kV) range, with almost no enhancement at megavoltage (MV) energies. Recent studies have shown that GNPs are not biologically inert, causing oxidative stress and even cell death, suggesting a possible biological mechanism for sensitization. The purpose of this study was to assess GNP radiosensitization at clinically relevant MV X-ray energies. METHODS AND MATERIALS: Cellular uptake, intracellular localization, and cytotoxicity of GNPs were assessed in normal L132, prostate cancer DU145, and breast cancer MDA-MB-231 cells. Radiosensitization was measured by clonogenic survival at kV and MV photon energies and MV electron energies. Intracellular DNA double-strand break (DSB) induction and DNA repair were determined and GNP chemosensitization was assessed using the radiomimetic agent bleomycin.
RESULTS: GNP uptake occurred in all cell lines and was greatest in MDA-MB-231 cells with nanoparticles accumulating in cytoplasmic lysosomes. In MDA-MB-231 cells, radiation sensitizer enhancement ratios (SERs) of 1.41, 1.29, and 1.16 were achieved using 160 kVp, 6 MV, and 15 MV X-ray energies, respectively. No significant effect was observed in L132 or DU145 cells at kV or MV energies (SER 0.97-1.08). GNP exposure did not increase radiation-induced DSB formation or inhibit DNA repair; however, GNP chemosensitization was observed in MDA-MB-231 cells treated with bleomycin (SER 1.38).
CONCLUSIONS: We have demonstrated radiosensitization in MDA-MB-231 cells at MV X-ray energies. The sensitization was cell-specific with comparable effects at kV and MV energies, no increase in DSB formation, and GNP chemopotentiation with bleomycin, suggesting a possible biological mechanism of radiosensitization. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21095075      PMCID: PMC3015172          DOI: 10.1016/j.ijrobp.2010.08.044

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  29 in total

1.  Gold nanoparticles as radiation sensitizers in cancer therapy.

Authors:  Devika B Chithrani; Salomeh Jelveh; Farid Jalali; Monique van Prooijen; Christine Allen; Robert G Bristow; Richard P Hill; David A Jaffray
Journal:  Radiat Res       Date:  2010-06       Impact factor: 2.841

Review 2.  New insights on cell death from radiation exposure.

Authors:  Kevin M Prise; Giuseppe Schettino; Melvyn Folkard; Kathryn D Held
Journal:  Lancet Oncol       Date:  2005-07       Impact factor: 41.316

3.  Estimation of tumour dose enhancement due to gold nanoparticles during typical radiation treatments: a preliminary Monte Carlo study.

Authors:  Sang Hyun Cho
Journal:  Phys Med Biol       Date:  2005-07-13       Impact factor: 3.609

4.  Oxygen radical formation and DNA damage due to enzymatic reduction of bleomycin-Fe(III).

Authors:  I Mahmutoglu; M E Scheulen; H Kappus
Journal:  Arch Toxicol       Date:  1987       Impact factor: 5.153

5.  The use of gold nanoparticles to enhance radiotherapy in mice.

Authors:  James F Hainfeld; Daniel N Slatkin; Henry M Smilowitz
Journal:  Phys Med Biol       Date:  2004-09-21       Impact factor: 3.609

6.  Radiosensitization of colon cancer cell lines by docetaxel: mechanisms of action.

Authors:  Amanda L Dunne; Carmel Mothersill; Tracy Robson; George D Wilson; David G Hirst
Journal:  Oncol Res       Date:  2004       Impact factor: 5.574

7.  Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation.

Authors:  K A Robertson; H A Bullock; Y Xu; R Tritt; E Zimmerman; T M Ulbright; R S Foster; L H Einhorn; M R Kelley
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

Review 8.  Cisplatin and radiotherapy in the treatment of locally advanced head and neck cancer--a review of their cooperation.

Authors:  Loredana Marcu; Tim van Doorn; Ian Olver
Journal:  Acta Oncol       Date:  2003       Impact factor: 4.089

9.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

Authors:  James A Bonner; Paul M Harari; Jordi Giralt; Nozar Azarnia; Dong M Shin; Roger B Cohen; Christopher U Jones; Ranjan Sur; David Raben; Jacek Jassem; Roger Ove; Merrill S Kies; Jose Baselga; Hagop Youssoufian; Nadia Amellal; Eric K Rowinsky; K Kian Ang
Journal:  N Engl J Med       Date:  2006-02-09       Impact factor: 91.245

10.  AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo.

Authors:  S R McKeown; M V Hejmadi; I A McIntyre; J J McAleer; L H Patterson
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

View more
  129 in total

1.  Gold nanoparticle induced vasculature damage in radiotherapy: Comparing protons, megavoltage photons, and kilovoltage photons.

Authors:  Yuting Lin; Harald Paganetti; Stephen J McMahon; Jan Schuemann
Journal:  Med Phys       Date:  2015-10       Impact factor: 4.071

Review 2.  Design and pharmacokinetical aspects for the use of inorganic nanoparticles in radiomedicine.

Authors:  Victor Puntes
Journal:  Br J Radiol       Date:  2015-10-23       Impact factor: 3.039

3.  Low Z target switching to increase tumor endothelial cell dose enhancement during gold nanoparticle-aided radiation therapy.

Authors:  Ross I Berbeco; Alexandre Detappe; Panogiotis Tsiamas; David Parsons; Mammo Yewondwossen; James Robar
Journal:  Med Phys       Date:  2016-01       Impact factor: 4.071

4.  Enhancement of radiation effect on cancer cells by gold-pHLIP.

Authors:  Michael P Antosh; Dayanjali D Wijesinghe; Samana Shrestha; Robert Lanou; Yun Hu Huang; Thomas Hasselbacher; David Fox; Nicola Neretti; Shouheng Sun; Natallia Katenka; Leon N Cooper; Oleg A Andreev; Yana K Reshetnyak
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

5.  Research perspectives: gold nanoparticles in cancer theranostics.

Authors:  Junjie Li; Sanjay Gupta; Chun Li
Journal:  Quant Imaging Med Surg       Date:  2013-12

6.  Gold Nanoparticles for Radiation Enhancement in Vivo.

Authors:  Samana Shrestha; Leon N Cooper; Oleg A Andreev; Yana K Reshetnyak; Michael P Antosh
Journal:  Jacobs J Radiat Oncol       Date:  2016-04-27

7.  Increased carcinoembryonic antigen expression on the surface of lung cancer cells using gold nanoparticles during radiotherapy.

Authors:  Romy Mueller; Sayeda Yasmin-Karim; Kaylie DeCosmo; Ana Vazquez-Pagan; Srinivas Sridhar; David Kozono; Juergen Hesser; Wilfred Ngwa
Journal:  Phys Med       Date:  2020-07-27       Impact factor: 2.685

Review 8.  Gold nanoparticles in breast cancer treatment: promise and potential pitfalls.

Authors:  Jihyoun Lee; Dev Kumar Chatterjee; Min Hyuk Lee; Sunil Krishnan
Journal:  Cancer Lett       Date:  2014-02-17       Impact factor: 8.679

9.  Computational Modeling and Clonogenic Assay for Radioenhancement of Gold Nanoparticles Using 3D Live Cell Images.

Authors:  Wonmo Sung; Yoon Jeong; Hyejin Kim; Hoibin Jeong; Clemens Grassberger; Seongmoon Jung; G-One Ahn; Il Han Kim; Jan Schuemann; Kangwon Lee; Sung-Joon Ye
Journal:  Radiat Res       Date:  2018-08-24       Impact factor: 2.841

10.  Theranostic gold nanoparticles modified for durable systemic circulation effectively and safely enhance the radiation therapy of human sarcoma cells and tumors.

Authors:  Daniel Y Joh; Gary D Kao; Surya Murty; Melissa Stangl; Lova Sun; Ajlan Al Zaki; Xiangsheng Xu; Stephen M Hahn; Andrew Tsourkas; Jay F Dorsey
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.